Latest News-Innovent Biologics,Inc Mediaroom_Page

Innovent Announces the Establishment of the Scientific Advisory Board

SAN FRANCISCO and SUZHOU, China, Aug. 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-08-09 08:04 4738

Updated Overall Survival Data and Biomarker Results from Sintilimab ORIENT-11 Study in First-Line Nonsquamous Non-Small Cell Lung Cancer Published in the Journal of Thoracic Oncology

SAN FRANCISCO and SUZHOU, China, Aug. 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent")...

2021-08-06 08:00 22947

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-26 08:00 6345

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 16, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-16 08:00 8058

Innovent and Ascentage Pharma Reach Multifaceted Strategic Agreement including Joint Commercialization of Olverembatinib in China, Joint Clinical Development on Multiple Products, and Equity Investment

SAN FRANCISCO and SUZHOU, China, July 14, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-14 23:48 16130

Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI323 (Anti-LAG-3/PD-L1 Bispecific Antibody) in Patients with Advanced Malignant Tumors

SAN FRANCISCO and SUZHOU, China, July 12, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-12 08:12 3966

Innovent Announces NMPA Acceptance of New Drug Application for the FGFR1/2/3 Inhibitor (Pemigatinib) for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement

SAN FRANCISCO, and SUZHOU, China, July 9, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-07-09 08:00 22985

Innovent and Laekna Therapeutics Enter a Partnership Agreement to Co-Develop Combination Therapy of Sintilimab and Afuresertib in Clinical Studies in China

SAN FRANCISCO and SUZHOU, China, July 6, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (...

2021-07-06 08:00 4461

Innovent Announces License Agreement with Synaffix in an ADC Technology Deal

SAN FRANCISCO and SUZHOU, China, June 29, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-29 08:00 5306

Innovent Announces the China NMPA Approval of TYVYT® (sintilimab injection) in Combination with BYVASDA® (bevacizumab biosimilar injection) as First-Line Therapy for People with Hepatocellular Carcinoma

SAN FRANCISCO and SUZHOU, China, June 28, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-28 08:00 5462

Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Glucagon-like Peptide-1 and Glucagon Receptor Dual Agonist in Overweight or Obese Chinese Participants at the American Diabetes Association's 81st Scientific Sessions

SAN FRANCISCO and SUZHOU, China, June 25, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-25 08:00 6246

Sintilimab in Combination with Chemotherapy Meets Overall Survival Primary Endpoint in the Global Phase 3 ORIENT-15 Study for the First-Line Treatment of Esophageal Squamous Cell Carcinoma

SAN FRANCISCO and SUZHOU, China, June 23, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-23 09:16 20442

Innovent Announces the Approval of Pemazyre® (pemigatinib) in Taiwan Market for the Treatment of Adults with Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with a FGFR2 Fusion or Rearrangement

SAN FRANCISCO and SUZHOU, China, June 22, 2021 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) ...

2021-06-22 08:00 18704

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

SAN FRANCISCO and SUZHOU, China, June 21, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-21 08:00 6372

Study Results of Sintilimab in Combination with Bevacizumab Biosimilar IBI305 for the First-Line Treatment of Hepatocellular Carcinoma Published in The Lancet Oncology

Innovent Announces First Patient Dosed in the Phase II Basket Trial of Taletrectinib for Solid Tumors with NTRK Fusion

SAN FRANCISCO and SUZHOU, China, June 18, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-18 08:00 3261

Innovent Announces First Overweight or Obese Subject Dosed in A Phase 2 Clinical Trial of IBI362 (a GLP-1 and Glucagon Receptor Dual Agonist) in China

SAN FRANCISCO and SUZHOU, China, June 15, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent"...

2021-06-15 12:00 4121

Innovent Biologics and IASO Biotherapeutics to Present Updated Data from its Anti-BCMA CAR-T Therapy in Relapsed/Refractory Multiple Myeloma at European Hematology Association (EHA) Congress

SAN FRANCISCO and SUZHOU, China, June 8, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-08 08:00 4529

Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 7567

Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 7706

Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021

SAN FRANCISCO and SUZHOU, China, June 7, 2021 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent",...

2021-06-07 08:00 7941